2.43
0.04 (1.67%)
| Penutupan Terdahulu | 2.39 |
| Buka | 2.39 |
| Jumlah Dagangan | 7,721 |
| Purata Dagangan (3B) | 13,993 |
| Modal Pasaran | 10,933,569 |
| Harga / Jualan (P/S) | 10.52 |
| Harga / Buku (P/B) | 0.720 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 May 2026 |
| Margin Keuntungan | -15.21% |
| Margin Operasi (TTM) | -937.65% |
| EPS Cair (TTM) | -6.00 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -96.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 65.87% |
| Nisbah Semasa (MRQ) | 2.28 |
| Aliran Tunai Operasi (OCF TTM) | -32.35 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.19 M |
| Pulangan Atas Aset (ROA TTM) | -21.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BioLineRx Ltd. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.50 |
|
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.08% |
| % Dimiliki oleh Institusi | 0.22% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nemes Rush Group Llc | 31 Dec 2025 | 250 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |